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itral Valve Abnormalities
n Congestive Heart Failure
n Interplay
etween Form and Function?*
evin D. O’Brien, MD, Daniel P. Fishbein, MD
eattle, Washington
itral regurgitation (MR) of at least mild severity is present
n up to 90% of patients with advanced congestive heart
ailure (CHF) due to systolic dysfunction (1). It had long
een assumed that MR results primarily from left ventric-
lar (LV) and mitral annular enlargement due to pathologic
emodeling, with contributions as well from regional wall
otion abnormalities and papillary muscle dysfunction in
atients with ischemic cardiomyopathy. It was recognized
everal years ago that, although diuretic and vasodilator
herapy in CHF had little effect on LV ejection fraction, one
f its major beneficial effects was a reduction in MR volume
ver the short (2) and intermediate (3) terms. Other
See page 54
pproaches to reduction of MR in CHF, such as mitral
alve reconstruction (4) or percutaneous mitral valve annu-
oplasty (5), are continuing to evolve, and their clinical
enefits are less certain (6). Another, more recently appre-
iated contributor to MR in patients with CHF is dyssyn-
hronous ventricular contraction, which is present in up to
0% of patients with CHF and depressed LV function (7).
eduction in MR may account for at least some of the
linical benefits seen in recent trials of biventricular pacing
8,9), although it represents but one of several measurable
emodynamic improvements seen with this therapy (10).
bnormal mitral valve composition in CHF. However, it
enerally also has been assumed that although cardiac
hamber sizes and mitral annular diameter increase in
atients with CHF, the structure and composition of the
itral valve leaflets remain normal. This assumption is
hallenged by important findings of Grande-Allen et al.
11), who report in this issue of the Journal that mitral valve
eaflets of patients with end-stage CHF have significant
lterations in both cellularity and extracellular matrix
ECM) composition. Grande-Allen et al. (11) compared
ontrol valves, obtained at autopsy from gender- and age-
atched patients, with mitral valves explanted at the time of
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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r. O’Brien was supported by grants DK02456 and HL30086 from the National
nstitutes of Health, Bethesda, Maryland.ardiac transplantation from patients with end-stage CHF.
hey found that, as compared with control valves, mitral
eaflets of the CHF patients had 78% greater deoxyribonu-
leic acid content, indicating increased cellularity, as well as
ignificant changes in ECM composition, including an 11%
ncrease in collagen content and a 59% increase in glycos-
minoglycans (GAGs) (11).
ardiac structural abnormalities and alterations in valve
omposition: cause and effect or consequences of a
ommon cause? The explanation for the changes in leaflet
omposition is perhaps more debatable. The authors’ pri-
ary hypothesis was that changes in cardiac and valvular
imensions and function, as measured by echocardiography,
ould correlate with valvular composition changes. The
mplicit assumption here is that, as suggested by previous
tudies of surgically induced MR (12,13), direct hemody-
amic forces are the major driver of valvular compositional
hange; neurohormones were not examined in those studies.
owever, the echocardiography/valvular composition cor-
elations were arguably less striking. In fact, in multivariate
odeling, the degree of MR was not correlated with any of
he observed valvular compositional changes. Instead, most
chocardiographic parameters found to correlate with leaflet
hanges were those that are themselves a consequence of
issue remodeling, such as left atrial, LV, and mitral annular
ize. This raises the possibility that, instead of direct
emodynamic forces representing the primary cause that
ffects changes in valvular composition, changes in cardiac
hamber size and changes in valvular composition result
rom a common cause, such as the neurohormonal activa-
ion that accompanies CHF (14). Within valves there are
egional differences in cell type, cell phenotype, and ECM
omposition, all of which have profound effects on cellular
esponses (15). Thus, it is not likely that different valve
egions would respond similarly to neurohormones.
The effect of neurohormonal activation on myocardial
brosis may occur primarily through effects on cardiac
yocytes, in which beta-adrenergic receptor overactivity
ncreases apoptosis (16) and beta-adrenergic blockade alters
he expression of myosin isoforms and calcium-handling
roteins (17). The stimulation of alpha-1-adrenergic recep-
ors has recently been shown to increase production of
onnective tissue growth factor (18), a growth factor that
as been implicated in many fibrosing diseases and which
ay be a downstream effector for the profibrotic growth
actor, transforming growth factor (TGF)-beta-1 (19).
owever, effects of catecholamines on cardiomyocytes are
nlikely to have any local effect on valve fibroblasts.
More direct effects on cardiac fibroblasts have been
hown with activation of the renin-angiotensin aldosterone
ystem. For example, aldosterone stimulates production of
ollagen types I and III by cardiac fibroblasts in vitro (20),
nd aldosterone antagonists have been shown to improve
urvival in CHF patients (21,22). Angiotensin II (AngII)
lso has been shown to stimulate collagen production by
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January 4, 2005:62–4 Editorial Commentardiac fibroblasts (20), an effect that may be due, in part, to
roduction of TGF-beta-1 in response to angiotensin II
ype 1 receptor (AT1R) stimulation (23). In addition, tumor
ecrosis factor-alpha, circulating levels of which are mark-
dly increased in CHF (24), upregulates cardiac fibroblast
T1R expression (25). Thus, not only are AngII levels
ncreased in CHF patients, but their cardiac fibroblasts
ikely also express increased AT1R.
However, the most striking ECM change in the CHF
alves of the Grande-Allen et al. (11) study was a 59%
ncrease in GAGs. Glycosaminoglycans are molecules com-
osed of repeating polysaccharides that can be found either
ovalently bound to a core protein to form proteoglycans
PGs) or without a core protein, as in the molecule
yaluronan. During the early phases of fibrosing injuries,
G and hyaluronan form a provisional matrix in response to
ocal expression of growth factors such as TGF-beta-1 and
latelet derived growth factor (15). The exact function of
any PGs is unknown, but one of them, biglycan, has been
mplicated in collagen fibrillogenesis both in vitro (26) and
n vivo (27), as well as in lipoprotein retention in athero-
clerotic plaques (28).
More recently, studies of a rat model of infarct-induced
HF have demonstrated that biglycan is the primary PG
xpressed by cardiac fibroblasts in noninfarcted myocar-
ium. The increased biglycan expression could be blocked
ither by an anti-TGF-beta-1 antibody or by the AT1R
ntagonist losartan, indicating that TGF-beta-1 released in
esponse to AT1R stimulation was responsible for the
ncreased biglycan expression (29,30).
asic science implications. The primary result of the
ovel findings of Grande-Allen et al. (11) should be to
timulate more detailed studies regarding the specific types
f cells and the specific ECM molecules that are present in
HF valves. For example, is the increased deoxyribonucleic
cid content due to fibroblast proliferation, or are inflam-
atory cells also present? It is likely that the fibroblasts
resent in the CHF valves have an altered phenotype, with
reater expression of AT1R and ECM. In addition, which
pecific GAG-containing matrix molecules are increased in
mount in CHF valves? One obvious candidate is biglycan
29,30). Moreover, how does CHF alter valvular content
nd activity of matrix-degrading enzymes, such as matrix
etalloproteinases, as well as of tissue inhibitors of
etalloproteinases?
Also, as the authors suggest, animal models may be
elpful in sorting out the relative effects of hemodynamic
actors as opposed to cytokines and growth factors in the
athogenesis of mitral valve abnormalities. However, it
ould be important to analyze not only the measures of
alve composition and regurgitation severity (12,13), but
lso the neurohormonal activation, as suggested by more
ecent studies of infarct-induced CHF (29,30). In addition,
t may also be helpful to include comparative analyses of
ortic valves in animal models of surgically induced CHF, as
itral valves would be subjected to relatively greater hemo-ynamic force changes but both mitral and aortic valves
ould be subjected to neurohormonal activation. If the
ffect of CHF on aortic valves is studied in humans, it will
e important to exclude valves with aortic sclerosis, as both
roteoglycan content and fibroblast AT1R expression are
ltered in that condition (31). Moreover, based on the
ndings of Grande-Allen et al. (11), future investigations
ould also be well advised to heed the authors’ warning that
areful consideration should be given before including valves
rom explanted, end-stage cardiomyopathy hearts as “nor-
al” controls.
linical implications. The clinical implications of the
tudy are less clear, as it is not yet known to what extent
itral valve composition changes might contribute to MR
everity in CHF patients. It is likely that changes in LV and
itral annular size and geometry due to pathologic remod-
ling, loading conditions, the severity of ventricular dyssyn-
hrony, and abnormalities in regional wall motion and
apillary muscle function are the major determinants of MR
everity in CHF. In addition, it is likely that the neurohor-
onal alterations responsible for pathologic myocardial and
nnular remodeling in CHF also play an important role in
ediating mitral valve compositional changes. In this re-
ard, in would be helpful to include measures of neurohor-
onal markers, in addition to echocardiographic studies, in
ubsequent studies of CHF mitral valve composition. More-
ver, pharmacologic therapies targeting neurohormonal ac-
ivation, which are known to improve myocardial cellular
nd ECM composition, may also effect favorable changes in
itral valve composition in CHF. Regardless, the study of
rande-Allen et al. (11) should lead to a paradigm shift in
ur view of mitral valvular structure and composition in
atients with CHF.
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